Philip M. Arlen

Philip M. Arlen publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Philip M. Arlen sits on this spectrum.

Philip M. Arlen D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Philip M. Arlen sits on this spectrum.

Best Publications

• Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

  Philip W. Kantoff;Thomas J. Schuetz;Brent A. Blumenstein;L. Michael Glode

  1185
  Citations

• Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti–Carcinoembryonic Antigen Immune Responses

  John L. Marshall;Robert J. Hoyer;Mary Ann Toomey;Kristen Faraguna

  531
  Citations

• Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer

  James L. Gulley;Philip M. Arlen;Anne Bastian;Steven Morin

  431
  Citations

• A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

  Joseph Paul Eder;Philip W. Kantoff;Kristin Roper;GuangXian Xu

  425
  Citations

• Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas

  John L. Marshall;James L. Gulley;Philip M. Arlen;Patricia K. Beetham

  421
  Citations

• Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

  Ravi A Madan;Mahsa Mohebtash;Philip M Arlen;Matteo Vergati

  367
  Citations

• Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.

  James L. Gulley;Philip M. Arlen;Ravi A. Madan;Kwong-Yok Tsang

  356
  Citations

• A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

  Philip M Arlen;James L Gulley;Catherine Parker;Lisa Skarupa

  353
  Citations

• Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.

  James Gulley;Alice P. Chen;William Dahut;Philip M. Arlen

  269
  Citations

• Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

  James L. Gulley;Philip M. Arlen;Kwong-Yok Tsang;Junko Yokokawa

  262
  Citations

• Cancer Vaccines: Moving Beyond Current Paradigms

  Jeffrey Schlom;Philip M. Arlen;James L. Gulley

  260
  Citations

• Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

  Ravi A Madan;Philip M Arlen;Mahsa Mohebtash;James W Hodge

  258
  Citations

• The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma

  M von Mehren;P Arlen;J Gulley;A Rogatko

  251
  Citations

• Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer

  Junko Yokokawa;Vittore Cereda;Cinzia Remondo;James L. Gulley

  210
  Citations

• Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 Transgenes in patients with recurrent CEA-expressing adenocarcinomas

  Margaret von Mehren;Philip Arlen;Kwong Y. Tsang;André Rogatko

  207
  Citations

• Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.

  Philip M. Arlen;Fernando Bianco;William L. Dahut;Anthony D'Amico

  190
  Citations

• Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy

  Ravi A. Madan;James L. Gulley;Jeffrey Schlom;Seth M. Steinberg

  172
  Citations

• A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer

  Mahsa Mohebtash;Kwong-Yok Tsang;Ravi A. Madan;Ngar-Yee Huen

  151
  Citations

• Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant

  Robert J. Lechleider;Philip M. Arlen;Kwong-Yok Tsang;Seth M. Steinberg

  151
  Citations

• Clinical Safety of a Viral Vector Based Prostate Cancer Vaccine Strategy

  Philip M. Arlen;Lisa Skarupa;Mary Pazdur;Mahesh Seetharam

  144
  Citations